Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02127775 · ClinicalTrials.gov registry record · Phase 1

Lesinurad Tablet Bioequivalence

A Phase 1 study, sponsored by Ardea Biosciences.

Completed
Registry status
Phase 1
Development phase
54
Enrollment target

NCT02127775 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 54 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02127775, a Phase 1 study, has completed, sponsored by Ardea Biosciences.

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target

Study Summary

This study will assess the bioequivalence of lesinurad tablets manufactured at two different sites.

Interventions

  • DRUG Lesinurad 400 mg (manufactured at Site 1)
  • DRUG Lesinurad 400 mg (manufactured at Site 2)

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2014-04
Est. Completion 2014-07
Phase Phase 1

Sponsor

Ardea Biosciences

32 total trials

What the Registry Record Tells You About NCT02127775

The ClinicalTrials.gov registry entry for NCT02127775 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Lesinurad 400 mg (manufactured at Site 1) is the first listed.

NCT02127775 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02127775 about?

NCT02127775 is a clinical study titled "Lesinurad Tablet Bioequivalence". This study will assess the bioequivalence of lesinurad tablets manufactured at two different sites.

What is the current status of trial NCT02127775?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2014-04. Estimated completion is 2014-07.

What interventions are being tested in trial NCT02127775?

The interventions under investigation include: Lesinurad 400 mg (manufactured at Site 1) (DRUG), Lesinurad 400 mg (manufactured at Site 2) (DRUG).

Who is sponsoring clinical trial NCT02127775?

This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.